Should your doctor check estrogen on TRT? Here's what the data says

What did @cbronsonmd actually say?

The creator argued that estradiol testing during TRT is pointless. His position: doctors should monitor body composition, hemoglobin and hematocrit, lipid panels, A1C, liver and kidney function, blood pressure, and symptom-based measures like libido. The punchline was direct: "the estradiol levels aren't going to tell you anything useful." That's a strong, testable claim, and it deserves scrutiny.

To be fair, the list of labs he does recommend is solid. Those are legitimate monitoring targets backed by clinical guidelines. The problem is the framing that estradiol is irrelevant, which overstates the case and could lead men to dismiss a hormone that actually matters in several clinical situations.

Does the science back this up?

Not entirely. The claim that estradiol is uninformative during TRT conflicts with a meaningful body of evidence. Estradiol in men is not a passive byproduct of testosterone metabolism. It plays active roles in bone density, cardiovascular function, sexual function, and mood.

Ramasamy et al. (2014, Journal of Urology) found that estradiol levels below 21.8 pg/mL were independently associated with low libido in men on TRT, even when testosterone was in range. That directly contradicts the idea that estradiol tells you nothing about the very symptom he says to ask about. Finkelstein et al. (2013, NEJM) went further, demonstrating that estrogen, not just testosterone, drives sexual desire and erectile function in men. Carani et al. (1999, NEJM) documented a man with aromatase deficiency whose sexual dysfunction only resolved after estrogen replacement, not testosterone. The data here is not ambiguous.

What did they get wrong, and what did they get right?

He got the recommended monitoring labs right. Body composition changes, hematocrit elevation, lipid shifts, glucose metabolism, and liver and kidney function are all appropriate TRT monitoring targets, consistent with Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism).

Where he went wrong is the blanket dismissal of estradiol. There is a legitimate critique buried in his position. Estradiol reference ranges for men vary widely between labs, and the clinical cutoffs for when to intervene are genuinely debated. Some physicians aggressively prescribe aromatase inhibitors based on estradiol numbers, which is its own problem. Leder et al. (2015, NEJM) showed that estrogen suppression in men impairs body composition and sexual function. So the criticism of over-treating estradiol? Reasonable. The claim that the number tells you nothing? That goes too far.

What should you actually know?

Estradiol monitoring is not mandatory for every TRT patient, but it is not useless either. The more nuanced picture: estradiol becomes clinically relevant when men report specific symptoms like low libido despite adequate testosterone, gynecomastia, water retention, or mood disturbance. In those cases, an estradiol level is not a curiosity, it is a diagnostic tool.

The stronger argument, which the creator gestures at without making cleanly, is that estradiol should not be treated as a number to reflexively suppress. Asymptomatic men with elevated estradiol do not automatically need aromatase inhibitors. The Endocrine Society does not recommend routine aromatase inhibitor use in TRT patients without clear clinical indication. So the takeaway is not "ignore estradiol" but rather "don't chase the number without clinical context."

• Estradiol below roughly 21 pg/mL is associated with low libido in TRT patients (Ramasamy, 2014)
• Both estrogen and testosterone contribute to sexual function in men (Finkelstein, 2013)
• Aggressive estradiol suppression can worsen body composition and sexual outcomes (Leder, 2015)